Browse > Article

Effect of Morin on the Pharmacokinetics of Nifedipine in Rats  

Lee, Chong-Ki (Department of Medical Management, Chodang University)
Choi, Jun-Shik (College of Pharmacy, Chosun University)
Publication Information
YAKHAK HOEJI / v.51, no.3, 2007 , pp. 169-173 More about this Journal
Abstract
The aim of this study was to investigate the effect of morin on the pharmacokinetics of nifedipine in rats. The pharmacokinetic parameters of nifedipine were measured after the oral administration of nifedipine (5 mg/kg) in the presence or absence of morin (1.5, 7.5 and 15 mg/kg, respectively). Compared to the control groups, the presence of 7.5 mg/kg and 15 mg/kg of morin significantly (p<0.05) increased the area under the plasma concentration-time curve (AUC) of nifedipine by 48.5${\sim}$68.2%, and the peak concentration (C$_{max}$,) of nifedipine by 59.9~84.2%. The absolute bioavailability(AB%) of nifedipine was significantly (p<0.05) increased by 21.5${\sim}$24.5% compared to the control (14.5%). While there was no significant change in the time to reach the peak plasma concentration (T$_{max}$) and the terminal half-life (T$_{1/2}$) of nifedipine in the presence of morin. It might be suggested that morin altered disposition of nifedipine by inhibition of both the first-pass metabolism and p-glycoprotein (P-gp) efflux pump in the small intestine of rats. In conclusion, the presence of morin significantly enhanced the oral bioavailability of nifedipine, suggesting that concurrent use of morin or morin-containing dietary supplement with nifedipine should require close monitoring for potential drug interaction.
Keywords
nifedipine; morin; pharmacokinetics; p-glycoprotein; first-pass metabolism;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sorkin, E. M., Clissold, S. P. and Brogden, R. N. : Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 30, 182 (1985)
2 Gan, S. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3ALike cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996)
3 Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999)
4 Endo, T., Kimura, O. and Sakata, M. : Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK. Toxicol. Appl. Pharmacol. 185, 166 (2002)
5 Dupuy, J., Larrieu, G., Sutra, J. F., Lespine A. and Alvinerie, M. : Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: Quercetin. Vet. Parasitol. 112, 337 (2003)   DOI   ScienceOn
6 Zhang, S. and Morris, M. E. : Effects of the flavonoids biochanin A, morin,phloretin, and silymarin on P-glycoproteinmediated transport. J. Pharmacol Exp. Ther. 304, 1258 (2003)   DOI   ScienceOn
7 Hodek, P., Trefil, P.and Stiborova, M. : Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139, 1 (2002)
8 Iribarne, C., Dreano, L. G., Bardou, J. F., Menez, G. and Berthou, F. : Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 117, 13 (1997)
9 Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996)
10 Walter, D. G., Gruchy, B. S., Renwick, A. G. and George, C. F. : The first pass metabolism of nifedipine in man. Br. J. Clin. Pharmacol. 18, 951 (1984)
11 Kolars, J. C., Schmiedlin-Ren, P., Dobbins 3rd, W. O., Schuetz, J., Wrighton S. A. and Watkins, P. B. : Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102, 1186 (1992)
12 Wacher, V. H., Silverman, J. A., Zhang Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998)
13 Nijveldt, R. J., van Nood, E., van Hoorn, D. E. C., Boelens, P. G. van Norren, K. and van Leeuwen, P. A. M. : Flavonoids: A review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74, 418 (2001)
14 Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)
15 Van Asperen, J., Van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen W. J. and Beijnen, J. H. : Enhanced oral bilavailability of diltiazem in mice treated with the pglycoprotein blocker. Br. J. Cancer. 76, 1181 (1997)
16 Hodek, P., Trefil, P., and Stiborova, M. : Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139, 1 (2002)
17 Buening, M. K., Chang, R. L., Huang, M. T., Fortner, J. G., Wood, A. W. and Conney, A. H. : Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res. 41, 67 (1981)
18 Li, X., Yun, J. K. and Choi, J. S. : Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm. Drug Dispos. 28, 151 (2007)   DOI   ScienceOn
19 Ford, J. M. : Modulators of multidrug resistance preclinical studies. Hematol. Oncol. Clin. N. Am. 9, 337 (1995)
20 Choi, J. S. and Han, H. K. : Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol. Res. 52, 386 (2005)   DOI   ScienceOn
21 Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine. 16, 203 (1983)
22 Biedler, J. L. and Riehm, H. : Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174 (1970)
23 Grundy, J. S., Kherani, R. and Foster, R. T. : Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J. Chromatogr. B. Biomed. Appl. 654, 146 (1994)
24 Choi, J. S. and Han, H. K. : Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. Int. J. Pharm. 23, 122 (2005)
25 Raemsch, K. D. and Sommer, J. C. : Pharmacokinetics and metabolism of nifedipine. Hypertension. 5, 18 (1983)
26 Guengerich, F. P., Brian, W. R. and Iwasaki, M. : Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J. Med. Chem. 4, 1838 (1991)
27 Dixon, R. A. and Steele, C. : Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci. 4, 394 (1999)
28 Doostdar, H., Burke, M. D. and Mayer, R. T. : Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144, 31 (2000)
29 Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)
30 Henry, P. D. : Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am. J. Cardiol. 46, 1047 (1980)
31 Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa D. T. and Guzelian, P. S. : Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029 (1987)
32 Fruehauf, J. P. and Manetta, A. : Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib. Gynecol. Obstet. 19, 39 (1994)
33 Zhang, S. and Morris, M. E. : Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoproteinmediated transport. J. Pharmacol. Exp. Ther. 304, 1258 (2003)   DOI   ScienceOn
34 Chaudhary, P. M. and Robinson, I. B. : Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85 (1991)
35 Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-- theoretical approach. Pharm. Res. 16, 225 (1999)
36 Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H. and van Tellingen, O. : Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6, 4416 (2000)
37 Hokama, N., Hobara, N., Sakai, M., Kameya, H., Ohshiro S. and Sakanashi, M. : Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J. Pharm. Pharmacol. 54, 821 (2002)